Literature DB >> 23082006

Acylated ghrelin as a provocative test for the diagnosis of GH deficiency in adults.

Valentina Gasco1, Guglielmo Beccuti, Chiara Baldini, Nunzia Prencipe, Stellina Di Giacomo, Alessandro Berton, Federica Guaraldi, Isabella Tabaro, Mauro Maccario, Ezio Ghigo, Silvia Grottoli.   

Abstract

OBJECTIVE: Insulin tolerance test (ITT) is the test of reference for the diagnosis of adult GH deficiency (GHD), although GHRH in combination with arginine (ARG) or GH secretagogues are considered equally reliable tests. Testing with GH secretagogue alone is, anyway, a potent stimulus exploring the integrity of hypothalamic pathways controlling somatotropic function. We therefore aimed to determine the diagnostic reliability of testing with ghrelin, the natural GH secretagogue.
METHODS: We studied the GH response (every 15 MIN from 15 TO +120 MIN) to acylated ghrelin (1G/KG I.V. AT 0MIN) IN 78 patients with a history of pituitary disease (49 male, 29 female; age (MEANS.D.): 52.1±18.7 years; BMI: 26.7±5.3 kg/m(2)). The lack of GH response to GHRH+ARG and/or ITT was considered the gold standard for the diagnosis of GHD. The best GH cut-off to ghrelin test, defined as the one with the best sensitivity (SE) and specificity (SP), was identified using the receiver-operating characteristic curve analysis.
RESULTS: The best GH cut-off to ghrelin test was 7.3 μg/l in lean subjects (SE 88.2%, SP 90.9%), 2.9 μg/l in overweight subjects (SE 92.6%, SP 100%) and 0.6 μg/l in obese subjects (SE 50%, SP 100%). The diagnostic accuracy was 89.3, 94.1 and 62.5% respectively.
CONCLUSIONS: Our data show that testing with acylated ghrelin represents a reliable diagnostic tool for the diagnosis of adult GHD, in lean and overweight subjects, if appropriate cut-off limits are assumed. Obesity strongly reduces GH response to ghrelin, GH weight-related cut-off limit and diagnostic reliability of the test.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23082006     DOI: 10.1530/EJE-12-0584

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  8 in total

1.  Acylated ghrelin as provocative test for the diagnosis of ACTH deficiency in patients with hypothalamus-pituitary disease.

Authors:  Valentina Gasco; Alessandro Berton; Mirko Parasiliti Caprino; Ioannis Karamouzis; Mauro Maccario; Ezio Ghigo; Silvia Grottoli
Journal:  Endocrine       Date:  2014-12-09       Impact factor: 3.633

2.  Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.

Authors:  Gulnara R Khakimova; Elena A Kozina; Valerian G Kucheryanu; Michael V Ugrumov
Journal:  Mol Neurobiol       Date:  2016-05-19       Impact factor: 5.590

Review 3.  Clinical review: The human experience with ghrelin administration.

Authors:  Margaret C Garin; Carrie M Burns; Shailja Kaul; Anne R Cappola
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

4.  Pituitary dysfunction after aneurysmal subarachnoid haemorrhage: course and clinical predictors—the HIPS study.

Authors:  L Khajeh; K Blijdorp; M H Heijenbrok-Kal; E M Sneekes; H J G van den Berg-Emons; A J van der Lely; D W J Dippel; S J C M M Neggers; G M Ribbers; F van Kooten
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-11-06       Impact factor: 10.154

Review 5.  Hypopituitarism after subarachnoid haemorrhage, do we know enough?

Authors:  Ladbon Khajeh; Karin Blijdorp; Sebastian Jcmm Neggers; Gerard M Ribbers; Diederik Wj Dippel; Fop van Kooten
Journal:  BMC Neurol       Date:  2014-10-14       Impact factor: 2.474

6.  Dynamic Ghrelin and GH serum levels during combined simultaneous arginine clonidine stimulation test in children with dwarfism.

Authors:  Guangzhong Zhou; Rongzeng Du
Journal:  Ital J Pediatr       Date:  2019-01-28       Impact factor: 2.638

7.  Diagnostic value of a ghrelin test for the diagnosis of GH deficiency after subarachnoid hemorrhage.

Authors:  K Blijdorp; L Khajeh; G M Ribbers; E M Sneekes; M H Heijenbrok-Kal; H J G van den Berg-Emons; A J van der Lely; F van Kooten; S J C M M Neggers
Journal:  Eur J Endocrinol       Date:  2013-09-14       Impact factor: 6.664

8.  Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency.

Authors:  J M Garcia; R Swerdloff; C Wang; M Kyle; M Kipnes; B M K Biller; D Cook; K C J Yuen; V Bonert; A Dobs; M E Molitch; G R Merriam
Journal:  J Clin Endocrinol Metab       Date:  2013-04-04       Impact factor: 5.958

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.